Merck (MRK) announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans, Louisiana from March 28-30. Results from the Phase 3 CORALreef AddOn trial evaluating the efficacy and safety of enlicitide, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hypercholesterolemia who are treated with a statin. Results from the Phase 2 CADENCE trial evaluating Winrevair in adults with CpcPH-HFpEF.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 15
- Merck price target raised to $150 from $135 at Wells Fargo
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- 3 Best ETFs to Invest In, According to AI Analyst, 03/10/2026
- Controversial Prasad leaving FDA, NYT reports